Massachusetts S2035 eliminates tax deductions for direct-to-consumer pharmaceutical marketing.
Massachusetts S2035 amends the state's tax code to eliminate deductions for direct-to-consumer pharmaceutical marketing. This includes all costs related to advertising prescription drugs and devices to patients in Massachusetts, such as media advertising, coupons, and outreach programs. The bill targets the deduction under section 162(a) of the Internal Revenue Code, specifically for marketing directed to consumers rather than licensed prescribers.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.